Results 41 to 50 of about 3,500 (185)
Rheumatology and Therapy, 2020 Introduction The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA).
Jacqueline M. Tarrant +8 more
doaj +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients [PDF]
, 2022 OBJECTIVES: This study was to determine whether the BILAG2004-Pregnancy Index (BILAG2004-P) has construct/criterion validity and is sensitive to change. METHODS: This was an observational multicentre study that recruited pregnant SLE patients.
Akil, Mohammed +7 more
core +1 more source
Frontiers in Bioscience-Landmark, 2023 Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today,
Maurizio Benucci +9 more
doaj +1 more source
Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis:A Brief Review [PDF]
, 2019 Rheumatoid arthritis is a chronic autoimmune disease that is a major public health challenge. The disease is characterised by inflammation of synovial joints and cartilage erosion, which lead to chronic pain, poor life quality and, in some cases ...
Chaplain, Mark A. J. +2 more
core +4 more sources
Effect of filgotinib on health-related quality of life in active psoriatic arthritis:a randomized phase 2 trial (EQUATOR) [PDF]
, 2020 To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.
Besuyen, Robin +11 more
core +1 more source
Arthritis Research & Therapy, 2018 Background The aim was to assess patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib during two phase 2b, 24-week, randomized, placebo-controlled studies.
Mark Genovese +6 more
doaj +1 more source
Медицинский совет, 2021 There has been clear progress in rheumatology in recent decades with the introduction of genetically engineered biological drugs (GEBDs) as well as targeted baseline anti-inflammatory drugs, which include Janus kinase inhibitors (i-JAKs). To date, i-JAKs
B. S. Belov +3 more
doaj +1 more source
Obstetric Outcomes in Women with Rheumatic Disease and COVID-19 in the Context of Vaccination Status [PDF]
, 2022 OBJECTIVE: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy.
Aguiar, Mathia Cecilia +64 more
core
Filgotinib for the treatment of rheumatoid arthritis [PDF]
Expert Opinion on Investigational Drugs, 2017 Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Taylor, P, Abdul Azeez, M, Kiriakidis, S
openaire +2 more sources